BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 19169493)

  • 21. Successful transition to sulfonylurea in neonatal diabetes, developmental delay, and seizures (DEND syndrome) due to R50P KCNJ11 mutation.
    Peña-Almazan S
    Diabetes Res Clin Pract; 2015 Apr; 108(1):e18-20. PubMed ID: 25678012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful transition to sulfonylurea therapy in two Iraqi siblings with neonatal diabetes mellitus and iDEND syndrome due to ABCC8 mutation.
    Ozsu E; Giri D; Seymen Karabulut G; Senniappan S
    J Pediatr Endocrinol Metab; 2016 Dec; 29(12):1403-1406. PubMed ID: 27849623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transient neonatal diabetes with two novel mutations in the KCNJ11 gene and response to sulfonylurea treatment in a preterm infant.
    Siklar Z; Ellard S; Okulu E; Berberoğlu M; Young E; Savaş Erdeve S; Mungan IA; Hacihamdioğlu B; Erdeve O; Arsan S; Oçal G
    J Pediatr Endocrinol Metab; 2011; 24(11-12):1077-80. PubMed ID: 22308870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Low doses of sulphonyluria as a successful replacement for insulin therapy in a patient with neonatal diabetes due to a mutation of KCNJ11 gene encoding Kir6.2].
    Ille J; Putarek NR; Radica A; Hattersley A; Ellard S; Dumić M
    Lijec Vjesn; 2010; 132(3-4):90-3. PubMed ID: 20540435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fetal macrosomia and neonatal hyperinsulinemic hypoglycemia associated with transplacental transfer of sulfonylurea in a mother with KCNJ11-related neonatal diabetes.
    Myngheer N; Allegaert K; Hattersley A; McDonald T; Kramer H; Ashcroft FM; Verhaeghe J; Mathieu C; Casteels K
    Diabetes Care; 2014 Dec; 37(12):3333-5. PubMed ID: 25231897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KCNJ11 in-frame 15-bp deletion leading to glibenclamide-responsive neonatal diabetes mellitus in a Chinese child.
    Yang W; Wei H; Sang Y
    J Pediatr Endocrinol Metab; 2013; 26(7-8):743-6. PubMed ID: 24266052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An ATP-binding mutation (G334D) in KCNJ11 is associated with a sulfonylurea-insensitive form of developmental delay, epilepsy, and neonatal diabetes.
    Masia R; Koster JC; Tumini S; Chiarelli F; Colombo C; Nichols CG; Barbetti F
    Diabetes; 2007 Feb; 56(2):328-36. PubMed ID: 17259376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Familial permanent neonatal diabetes with KCNJ11 mutation and the response to glyburide therapy--a three-year follow-up.
    Begum-Hasan J; Polychronakos C; Brill H
    J Pediatr Endocrinol Metab; 2008 Sep; 21(9):895-903. PubMed ID: 18924582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DEND Syndrome with Heterozygous KCNJ11 Mutation Successfully Treated with Sulfonylurea.
    Cho JH; Kang E; Lee BH; Kim GH; Choi JH; Yoo HW
    J Korean Med Sci; 2017 Jun; 32(6):1042-1045. PubMed ID: 28480665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sulfonylurea therapy in two Korean patients with insulin-treated neonatal diabetes due to heterozygous mutations of the KCNJ11 gene encoding Kir6.2.
    Kim MS; Kim SY; Kim GH; Yoo HW; Lee DW; Lee DY
    J Korean Med Sci; 2007 Aug; 22(4):616-20. PubMed ID: 17728498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful sulfonylurea treatment of an insulin-naïve neonate with diabetes mellitus due to a KCNJ11 mutation.
    Wambach JA; Marshall BA; Koster JC; White NH; Nichols CG
    Pediatr Diabetes; 2010 Jun; 11(4):286-8. PubMed ID: 19656320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diabetes and hypoglycaemia in young children and mutations in the Kir6.2 subunit of the potassium channel: therapeutic consequences.
    Flechtner I; de Lonlay P; Polak M
    Diabetes Metab; 2006 Dec; 32(6):569-80. PubMed ID: 17296510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes.
    Gloyn AL; Pearson ER; Antcliff JF; Proks P; Bruining GJ; Slingerland AS; Howard N; Srinivasan S; Silva JM; Molnes J; Edghill EL; Frayling TM; Temple IK; Mackay D; Shield JP; Sumnik Z; van Rhijn A; Wales JK; Clark P; Gorman S; Aisenberg J; Ellard S; Njølstad PR; Ashcroft FM; Hattersley AT
    N Engl J Med; 2004 Apr; 350(18):1838-49. PubMed ID: 15115830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy.
    Koster JC; Cadario F; Peruzzi C; Colombo C; Nichols CG; Barbetti F
    J Clin Endocrinol Metab; 2008 Mar; 93(3):1054-61. PubMed ID: 18073297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No beta cell desensitisation after a median of 68 months on glibenclamide therapy in patients with KCNJ11-associated permanent neonatal diabetes.
    Iafusco D; Bizzarri C; Cadario F; Pesavento R; Tonini G; Tumini S; Cauvin V; Colombo C; Bonfanti R; Barbetti F
    Diabetologia; 2011 Oct; 54(10):2736-8. PubMed ID: 21822789
    [No Abstract]   [Full Text] [Related]  

  • 36. Transition from insulin to glyburide in a 4-month-old girl with neonatal diabetes mellitus caused by a mutation in KCNJ11.
    Chan YM; Laffel LM
    Pediatr Diabetes; 2007 Aug; 8(4):235-8. PubMed ID: 17659066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful sulfonylurea treatment of a neonate with neonatal diabetes mellitus due to a new KCNJ11 mutation.
    Ješić MM; Ješić MD; Maglajlić S; Sajić S; Necić S
    Diabetes Res Clin Pract; 2011 Jan; 91(1):e1-3. PubMed ID: 21056492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continuous spectrum of glucose dysmetabolism due to the KCNJ11 gene mutation-Case reports and review of the literature.
    He B; Li X; Zhou Z
    J Diabetes; 2021 Jan; 13(1):19-32. PubMed ID: 32935446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transient neonatal diabetes mellitus is associated with a recurrent (R201H) KCNJ11 (KIR6.2) mutation.
    Colombo C; Delvecchio M; Zecchino C; Faienza MF; Cavallo L; Barbetti F;
    Diabetologia; 2005 Nov; 48(11):2439-41. PubMed ID: 16205880
    [No Abstract]   [Full Text] [Related]  

  • 40. Personalized medicine switching from insulin to sulfonylurea in permanent neonatal diabetes mellitus dictated by a novel activating ABCC8 mutation.
    Mak CM; Lee CY; Lam CW; Siu WK; Hung VC; Chan AY
    Diagn Mol Pathol; 2012 Mar; 21(1):56-9. PubMed ID: 22306677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.